Original news and analysis on international IP policy
By Kaitlin Mara United States Trade Representative Susan Schwab on Tuesday told reporters at the World Trade Organization that the United States does not plan to negotiate this week on the extension of high-level protections on product names associated with…
By William New and Kaitlin Mara Intellectual property issues have been a topic of debate at the World Trade Organization ministerial negotiations since Friday and while there have been no changes in positions there has been some talk of looking…
[Note: IP issues may be the subject of meetings between ministers and WTO DG Lamy over this weekend, according to sources.] By Kaitlin Mara and William New A new draft of proposed modalities for negotiating three intellectual property issues at…
By Liza Porteus Viana for Intellectual Property Watch
When Biotechnology Industry Organization CEO Jim Greenwood meets with members of the United States Congress to talk to them about follow-on biologics, he brings a graphic model of an aspirin and a DVD showing the complex molecules of a biologic drug. He uses these visuals to help explain the differences between traditional chemical drugs and newer, cutting-edge biological ones being used in many breakthrough therapies for cancer, multiple sclerosis, HIV/AIDS, and other diseases.
The differences between traditional chemical drugs and biological ones is the crux of the debate going on in the United States as Congress and the Food and Drug Administration (FDA) try to create a regulatory pathway that gives consumers greater access to cheaper, generic biological drugs, but still spurs innovation and protects innovator patent claims.
"When the legislation was introduced at the beginning of this Congress, most pundits expected that we'd oppose it," said Greenwood, a former House representative from Pennsylvania, told Intellectual Property Watch. "But that was a mistake the pharmaceutical industry made in the '80s - trying to resist the notion you could safely make generics …our view at BIO is that we need to follow the science, and science says you can make follow-on biologics that can be safe and can save the consumer money and therefore we support it."
By Kaitlin Mara A confidential draft text circulated recently among some World Trade Organization members reveals an attempt to consolidate separate proposals aimed at the protection of product names with location-related associations and characteristics (called geographical indications) and at the…
By Kaitlin Mara
Intellectual property is a useful leveraging tool for developing countries eager to see the creation of a global access and benefit-sharing regime on genetic resource use, said a recent panel on biodiversity protections in international law.
"Benefit-sharing was viewed as an integral part of the main bargain between developed and developing countries" when the Convention on Biological Diversity (CBD) was first formed, said Timothy Hodges, a Canadian official who co-chairs an access and benefit-sharing working group under the CBD.
By Kaitlin Mara An association of producers of geographical indications – product names associated with a particular place and characteristics – is promoting the idea that extending the high-level protection of geographic indications currently enjoyed by wines and spirits to…
By Kaitlin Mara The final decisions of the ninth and most recent meeting of the Convention on Biological Diversity’s (CBD) organising body have been released, which include the breakthrough results of a work plan for achieving an international access and…
By Tatum Anderson for Intellectual Property Watch Indian generic manufacturers may be allowed to export a cheaper HIV/AIDS treatment to middle-income countries if US pharmaceutical company Gilead fails to win a patent for the drug in India. And a turnaround…
[Note: the final version of the chair’s text is now available on the WIPO website.] By William New World Intellectual Property Organization members discussing a work plan for the committee on patent law on Thursday finished work for the year…